✦ LIBER ✦

PCN86 Cost-Utility Analysis of Nilotinib Compared to Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase

✍ Scribed by Inocencio, T.J.; Seetasith, A.; Newland, A.; Bose, P.; Holdford, D.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN13 Cost-Effectiveness Analysis of Nil

✍ Niu, X.; Hay, J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN92 Cost-Effectiveness of Nilotinib Ve

✍ R. Yagudina; A. Kulikov; I. Komarov 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PCN57 Cost Effectiveness of Nilotinib Ve

✍ Tse, V.; Liu, H.; Botteman, M.; Mcghee, S.; Lee, V.W.; Lee, K.K. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

PCN124 COST-UTILITY ANALYSIS OF DASATINI

✍ E Asano; M Nita; A Moellmann-Coelho; R Rached; B Donato; E Rahal 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Imatinib for newly diagnosed chronic-pha

✍ Tadashi Nagai; Jin Takeuchi; Nobuaki Dobashi; Yuzuru Kanakura; Shuichi Taniguchi 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 284 KB

PCN11 COST-UTILITY ANALYSIS OF DASATINIB

✍ JFS Logman; MJ Taylor; K Neumann; L Kutikova; KH Cerri; BA Van Hout; T Kühr 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB